Nakae R, Matsuzaki S, Serada S, et al. - The activity of tumoral CD70 in uterine leiomyosarcoma was examined and the antitumor activity of CD70–antibody-drug conjugate treatment in uterine leiomyosarcoma was assessed. Researchers screened target membrane proteins by profiling and comparing membrane protein expression in 3 uterine leiomyosarcoma cell lines (SK-UT-1, SK-LMS-1, and SKN) and normal uterine myometrium cells; they employed the isobaric tags for relative and absolute quantitation labeling method. In the membrane proteins in uterine leiomyosarcoma cell lines and clinical samples, CD70 expression was examined using Western blotting, fluorescence-activated cell sorting analyses, and immunohistochemistry. Findings suggest that CD70 is highly express by uterine leiomyosarcoma tumors. Tumor growth was significantly inhibited in the SK-LMS-1 xenograft mouse model and patient-derived xenograft mouse model in correlation with applying CD70–antibody-drug conjugate. This suggests a potential therapeutic implication of targeted therapy with CD70–antibody-drug conjugate in the treatment of uterine leiomyosarcoma.